Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus

Immunology and Cell Biology

Volumn 79, Issue 6, 2001, Pages 569-575

  Feng, Carl G ^a   Blanchard, Tom J ^b   Smith, Geoffrey L ^b   Hill, Adrian V S ^c   Britton, Warwick J ^a,d  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CD8+ T lymphocytes; Modified vaccinia virus Ankara; Mycobacterium; Prime boost immunization; Vaccinia virus

Indexed keywords

BACTERIAL ANTIGEN; EPITOPE; GAMMA INTERFERON; PLASMID DNA; PROTEIN; PROTEIN MPT64; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; VACCINIA VIRUS; VIRUS ATTENUATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIGENS, BACTERIAL; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL VACCINES;

ACTINOBACTERIA (CLASS); ANIMALIA; ANKARA; BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE; VACCINIA; VACCINIA VIRUS;

EID: 0035187997     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2001.01042.x     Document Type: Article

References (35)

1. Tuberculosis in patients with human immunodeficiency virus infection
2. Global surveillance for anti-tuberculosis drug resistance, 1994-97
3. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature
4. Disseminated bacillus Calmette-Guerin infections in patients with primary immunodeficiencies
5. Disseminated bacille Calmette-Guerin disease after vaccination: Case report and review
6. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice
7. Vaccination against tuberculosis by DNA injection
8. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
9. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection
10. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function
11. A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listeria monocytogenes infection
12. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection
13. Complications of smallpox vaccination, 1968
14. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
15. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism
16. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus
17. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
18. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
19. Future vaccines for HIV
20. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
21. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
22. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
23. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
24. Immunization of mice with mycobacterial culture filtrate proteins
25. Differential T-cell responses to mycobacterial secreted proteins distinguish between BCG vaccination and infection with Mycobacterium tuberculosis
26. Dendritic cells infected with Mycobacterium bovis bacille Calmette Guerin activate CD8+ T cells with specificity for a novel mycobacterial epitope
27. E. Coli β-glucuronidase (Gus) as a marker for recombinant vaccinia viruses
28. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis
29. Disseminated tuberculosis in interferon gamma gene-disrupted mice
30. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
31. Nonreplicating vaccinia vector efficiently expresses recombinant genes
32. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins - Implications for use as a human vaccine
33. Induction of bystander T cell proliferation by viruses and type I interferon in vivo
34. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
35. + T cells using heterologous prime-boost immunisation strategies